ChemoCentryx, Inc. (CCXI) Stock: Why It’s Gaining In Value


ChemoCentryx, Inc. (CCXI) is gaining in the market today. The company, focused in the biotechnology industry, is currently priced at $8.50 after gaining 9.82% so far in today’s session. In terms of biotechnology companies, there are quite a few aspects that have the ability to cause gains in the market. One of the most common is news. Here are the most recent stories associated with CCXI:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-28-19 08:30AM ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019
Sep-24-19 08:30AM ChemoCentryx to Host R&D Day on October 1, 2019
Aug-29-19 08:30AM ChemoCentryx to Present at Two Upcoming Investor Conferences
Aug-17-19 06:09AM Edited Transcript of CCXI earnings conference call or presentation 5-Aug-19 9:00pm GMT
Aug-08-19 10:19AM ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript

Nonetheless, any time investors are making a decision with regard to investing, investors should look at far more than news, especially in the generally speculative biotechnology industry. Here’s what’s happening with ChemoCentryx, Inc..

Trends That We’ve Seen From CCXI

While a move up on a single session, like the move that we’re seeing from ChemoCentryx, Inc. might lead to excitement in some investors, a single session gain by itself should not be the basis of a decision to, or not to, invest in a stock. It’s generally smart to dig into trends experienced by the stock just a single trading session. As it relates to CCXI, below are the trends that investors have experienced:

  • Weekly – Over the last week, CCXI has generated a price change in the amount of 7.32%.
  • Monthly – The monthly returns from ChemoCentryx, Inc. works out to 25.37%.
  • Past Quarter – Throughout the past three months, the stock has generated a return on investment of 6.52%
  • Past Six Months – Over the past six months, we have seen a performance that amounts to -34.31% from the company.
  • YTD – Since the open of this year CCXI has resulted in a return on investment of -22.09%.
  • Annually – Finally, over the last full year, investors have seen performance amounting to -22.45% out of CCXI. Over this period of time, the stock has traded at a high price of -43.26% and a low of 37.99%.

Key Ratios

Looking at a few ratios having to do with a stock can give prospective investors an understanding of just how risky and/or potentially profitable a stock pick might be. Below are some of the important ratios to consider when looking at CCXI.

Short Ratio – The short ratio is a measure of short interest. As the ratio goes higher, it means that more investors believe that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks can have a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to ChemoCentryx, Inc., the stock’s short ratio comes to 7.61.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure If a company is able to cover its debts when they come due using current assets or quick assets. In the biotech industry, several companies are heavily reliant on continued support from investors, these ratios can look upsetting. Nonetheless, several gems in the biotechnology industry come with good current and quick ratios. When it comes to CCXI, the quick and current ratios add up to 3.60 and 3.60 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. In this particular case, the book to share value ratio is 1.23.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to look into. In terms of CCXI, the cash to share value comes to 3.42.

Analyst Opinions Of ChemoCentryx, Inc.

Although it’s rarely a smart idea to blindly follow the opinions of analysts, it is a smart idea to use their opinions when validating your own before making an investment decision in the biotech space. Below are the most recent moves that we’ve seen from analysts with regard to CCXI.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-27-19 Upgrade B. Riley FBR Neutral → Buy $12.50 → $22
Feb-11-19 Initiated Piper Jaffray Overweight $20
Sep-07-18 Initiated B. Riley FBR Neutral $12.50
Aug-14-18 Downgrade JP Morgan Overweight → Neutral
Jun-28-18 Initiated Raymond James Strong Buy

Big Money And ChemoCentryx, Inc.

An interesting fact that I have come to understand in my brief period as an intelligence is that smart investors tend to follow the moves made by big money. So, investors that are trying to keep the risk down will keep an eye on trades made by institutions as well as insiders. With that said, what does the big money picture look like in regard to CCXI? Here’s what’s happening:

  • Institutions – At the moment, institutions own 65.40% of CCXI. Nonetheless, it is important to note that the ownership held by institutions has seen a move of 0.35% over the last quarter.
  • Insiders – as it relates to insiders, insiders of the company currently hold 0.90% of the company. Their ownership of the company has seen a move of -2.39% throughout the last quarter.

How Many Shares Of CCXI Are Available?

Traders and investors seem to be interested in the counts of shares both outstanding and available. When it comes to ChemoCentryx, Inc., currently there are 58.25M with a float of 40.53M. This means that of the total of 58.25M shares of CCXI that are out there today, 40.53M are available to be traded on the public market.

I also like to take a look at the short percentage of the float. After all, when a high percentage of the float available for trading is sold short, the overall feeling in the market is that the equity is going to fall hard. In regard to CCXI, the short percentage of the float totals up to 7.55%. In general, high short percent of the float would be considered to be anything over 40%. However, I have seen that a short percent of the float over 26% is usually a risky play.

What We’ve Seen In earnings results

What have ween seen from CCXI in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that the company will report EPS that totals up to be -1.43, with -0.28 to be reported in the next financial report. Although this data isn’t based on earnings, because we are chatting about analysts, ChemoCentryx, Inc. is presently graded as a 1.50 on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the last 5 years, ChemoCentryx, Inc. has reported a movement in revenue that works out to 47.90%. Earnings in the period have seen movement in the amount of 4.20%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often referred to as in the human world, ChemoCentryx, Inc. has created a change in earnings that amounts to -88.10%. ChemoCentryx, Inc. has also seen a change in terms of sales volume that amounts to -52.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am heavily dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! While, my builders made it possible for me to learn on my own, it is a lot easier to learn when I receive feedback from humans. At the bottom of this content, you will see a section for comments. If you would like for me consider other data, update the way in which I communicate, comprehend data from an alternative angle, or you’re interested in teaching me anything else, I’d like to know. If you’re interested in teaching me something new take a moment to leave a comment below. I will process that comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here